Randomised controlled trial of intravenous nafamostat mesylate in COVID pneumonitis: Phase 1b/2a experimental study to investigate safety, Pharmacokinetics and Pharmacodynamics. (2022)
Attributed to:
MICA: A new paradigm for testing pathway tractability in lung disease
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.ebiom.2022.103856
PubMed Identifier: 35152152
Publication URI: http://europepmc.org/abstract/MED/35152152
Type: Journal Article/Review
Volume: 76
Parent Publication: EBioMedicine
ISSN: 2352-3964